Nyxoah SA (NYXH)
NASDAQ: NYXH · Real-Time Price · USD
4.890
+0.080 (1.66%)
Dec 5, 2025, 4:00 PM EST - Market closed
Nyxoah Revenue
Nyxoah had revenue of 1.97M EUR in the quarter ending September 30, 2025, with 55.77% growth. This brings the company's revenue in the last twelve months to 5.64M, up 10.96% year-over-year. In the year 2024, Nyxoah had annual revenue of 4.52M with 3.98% growth.
Revenue (ttm)
5.64M EUR
Revenue Growth
+10.96%
P/S Ratio
32.38
Revenue / Employee
30,714 EUR
Employees
184
Market Cap
214.23M USD
Revenue Chart
* This company reports financials in EUR.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
NYXH News
- 3 days ago - Publication relating to transparency notifications - GlobeNewsWire
- 8 days ago - Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 10 days ago - Nyxoah's Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule - GlobeNewsWire
- 15 days ago - Information on the total number of voting rights and shares - GlobeNewsWire
- 22 days ago - Nyxoah SA (NYXH) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio - GlobeNewsWire
- 22 days ago - Nyxoah Reports Third Quarter 2025 Financial and Operating Results - GlobeNewsWire
- 4 weeks ago - Nyxoah to Participate in the Stifel 2025 Healthcare Conference - GlobeNewsWire